On June 14, 2012, the Supreme Court of Canada ("SCC") denied leave to hear an appeal involving section 8 of the Patented Medicines (Notice of Compliance) Regulations. The case involves Merck and Apotex regarding the drug lovastatin. The SCC's summary of the leave case can be found here.
Consistent with its practice, the SCC did not provide reasons for the denial of the leave application.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.